4C Medical is a medical device company developing minimally invasive technologies for structural heart disease, focusing initially on mitral regurgitation (MR) therapy and subsequently on tricuspid regurgitation therapy. Subject to regulatory approvals, the Company's AltaValve would be the first MR treatment with atrial-only fixation that is designed to minimize known issues associated with current TMVR technologies, which rely on placement and fixation within the native mitral annulus.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 04/04/22 | $35,400,000 | Series C |
MicroPort CardioFlow Medtech | undisclosed |
